---
title: "Top Bank Names 6 Stocks With Major Catalysts Ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300811363.md"
description: "William Blair's latest conviction list highlights six stocks with major catalysts in October, including earnings, product expansions, and clinical data. Fintech picks Chime (CHYM) and Dave (DAVE) are noted for user growth and tech improvements. Remitly (RELY) is selected due to valuation retreat. TheRealReal (REAL) faces refinancing and results. Healthcare pick Dianthus (DNTH) awaits Phase II data, while Netskope (NTSK) is chosen for cybersecurity/AI demand and revenue trends."
datetime: "2026-10-02T16:16:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300811363.md)
  - [en](https://longbridge.com/en/news/300811363.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300811363.md)
generator: "portal-rs"
---

# Top Bank Names 6 Stocks With Major Catalysts Ahead

William Blair's latest conviction list puts six stocks under renewed analyst attention for October, with potential earnings, product expansion, clinical data and valuation serving as the main catalysts, according to a Thursday note.

The fintech picks include Chime Financial (CHYM) and Dave (DAVE). Analyst Andrew Jeffrey pointed to rising activity among Chime users and adoption of MyPay and Instant Loans. At Dave, he highlighted improving credit performance and the company's Cash AI v6.0 technology.

In payments, Cristopher Kennedy selected Remitly Global (RELY), citing the stock's roughly 20% retreat from recent highs and the company's position in the fragmented cross-border payments market.

Consumer internet company TheRealReal (REAL) was chosen by Dylan Carden, who sees upcoming refinancing, November results and distribution-center improvements as possible catalysts.

Healthcare analyst Myles Minter added Dianthus Therapeutics (DNTH) ahead of Phase II data, while Jonathan Ho picked Netskope (NTSK) based on recurring-revenue trends, valuation and demand for cybersecurity and AI products.

### Related Stocks

- [CHYM.US](https://longbridge.com/en/quote/CHYM.US.md)
- [DAVE.US](https://longbridge.com/en/quote/DAVE.US.md)
- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)
- [NTSK.US](https://longbridge.com/en/quote/NTSK.US.md)
- [RELY.US](https://longbridge.com/en/quote/RELY.US.md)
- [REAL.US](https://longbridge.com/en/quote/REAL.US.md)

## Related News & Research

- [Why Netskope Stock Crushed it This Week](https://longbridge.com/en/news/299498540.md)
- [As fintechs nab bank charters, what's happening to BaaS?](https://longbridge.com/en/news/299681353.md)
- [Goldman Sachs Sticks to Their Buy Rating for Chime Financial, Inc. Class A (CHYM)](https://longbridge.com/en/news/301706350.md)
- [What Remitly Stock's Conviction List Addition Means For Shareholders](https://longbridge.com/en/news/301211060.md)
- [Dave’s Success Has Investors Split](https://longbridge.com/en/news/300126207.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**